Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. (Q40447501)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. |
scientific article |
Statements
1 reference
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. (English)
1 reference
Gerd R Burmester
1 reference
Yong Lin
1 reference
Rahul Patel
1 reference
Janet van Adelsberg
1 reference
Erin K Mangan
1 reference
Neil M H Graham
1 reference
Hubert van Hoogstraten
1 reference
Deborah Bauer
1 reference
Juan Ignacio Vargas
1 reference
Eun Bong Lee
1 reference
17 November 2016
1 reference
1 reference
76
1 reference
5
1 reference
840-847
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference